Kalaris Therapeutics, Inc. (KLRS) Stock Analysis

Kalaris Therapeutics, Inc. (KLRS) is a publicly traded company in the HEALTHCARE sector. It trades at $4.65, carries a market capitalization of $116.58M. This page summarizes the public market data, fundamentals, and frequently asked questions for KLRS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.65
• Market Cap: $116.58M
• EPS: $-0.79
• 52-Week High: $11.88
• 52-Week Low: $2.14

Market Sentiment

Kalaris Therapeutics, Inc. currently has a Bullish sentiment score of 0.31.

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Palo Alto, California, dedicated to developing innovative therapies for neovascular retinal diseases, thereby addressing critical unmet medical needs in ocular health. The firm harnesses advanced research and development capabilities to create transformative treatments aimed at improving patient outcomes. With a strong pipeline and a team of seasoned professionals, Kalaris is well-positioned to make signific...

GNG Research Analysis

GNG Research scores Kalaris Therapeutics, Inc. (KLRS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KLRS.

Frequently Asked Questions

Does KLRS pay dividends?

Kalaris Therapeutics, Inc. (KLRS) does not currently pay a regular dividend.

What is KLRS's market cap?

Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $116.58M with a current stock price of $4.65.